Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers? - Université de Reims Champagne-Ardenne Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2022

Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?

Abstract

Carbamylation is a nonenzymatic post-translational modification resulting from the reaction between cyanate, a urea by-product, and proteins. In vivo and in vitro studies have demonstrated that carbamylation modifies protein structures and functions, triggering unfavourable molecular and cellular responses. An enhanced formation of carbamylation-derived products (CDPs) is observed in pathological contexts, especially during chronic kidney disease (CKD), because of increased blood urea. Significantly, studies have reported a positive correlation between serum CDPs and the evolutive state of renal failure. Further, serum concentrations of carbamylated proteins are characterized as strong predictors of mortality in end-stage renal disease patients. Over time, it is likely that these modified compounds become aggravating factors and promote long-term complications, including cardiovascular disorders and inflammation or immune system dysfunctions. These poor clinical outcomes have led researchers to consider strategies to prevent or slow down CDP formation. Even if growing evidence suggests the involvement of carbamylation in the pathophysiology of CKD, the real relevance of carbamylation is still unclear: is it a causal phenomenon, a metabolic consequence or just a biological feature? In this review, we discuss how carbamylation, a consequence of renal function decline, may become a causal phenomenon of kidney disease progression and how CDPs may be used as biomarkers.
Fichier principal
Vignette du fichier
ijms-23-00574-v2.pdf (3.7 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-04099259 , version 1 (16-05-2023)

Licence

Identifiers

Cite

Laëtitia Gorisse, Stéphane Jaisson, Christine Piétrement, Philippe Gillery. Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?. International Journal of Molecular Sciences, 2022, 23 (1), pp.574. ⟨10.3390/ijms23010574⟩. ⟨hal-04099259⟩

Collections

CNRS URCA MEDYC
24 View
25 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More